An international research team led by the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects. Their new material could be developed into an antimicrobial drug to treat patients with antibioticresistant infections.
This finding was reported in the scientific journal Nature Communications.
Superbugs that are resistant to antibiotics are a serious health threat. According to the UK Review on Antimicrobial Resistance, superbugs kill around 700,000 people worldwide each year. By 2050, 10 million people could die each year if existing antibiotics continue to lose their effectiveness.
“There is an urgent global need for new antimicrobials that are effective against superbugs. The situation has become more acute because bacteria are starting to develop resistance to the last-line antibiotics, which are given only to patients infected with bacteria resistant to available antibiotics,” said Professor Jackie Y. Ying, Executive Director of IBN.
The research community is trying to develop alternatives to antibiotics using synthetic polymers. However, the antimicrobial polymers developed so far are either too toxic for clinical use, not biodegradable or can only target one type of bacteria.
To address this problem, Dr Yi Yan Yang from IBN brought together a multidisciplinary research team from the US, China and Singapore to develop a new class of antimicrobial polymers called guanidinium-functionalized polycarbonates with a unique killing mechanism that can target a broad range of multidrug-resistant bacteria. It is biodegradable and non-toxic to human cells.
The polymer kills bacteria in the following way. First, the polymer binds specifically to the bacterial cell. Then, the polymer is transported across the bacterial cell membrane into the cytoplasm, where it causes precipitation of the cell contents (proteins and genes), resulting in cell death.
The team tested the polymers on mice infected with five hard-to-treat multidrug-resistant bacteria: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, methicillinresistant Staphylococcus aureu and Pseudomonas aeruginosa. These superbugs are commonly acquired by patients in the hospitals and can cause systemic infections that lead to septic shock and multiple organ failure. The results showed that the bacteria were effectively removed from the mice and no toxicity was observed.
The researchers then further tested the effectiveness of the polymers on mice with two types of systemic infections caused by superbugs: peritonitis (an infection of the stomach’s inner lining) and lung infections from Pseudomonas aeruginosa. The polymers eliminated the bacterial infections in both groups of mice with negligible toxicity.
Dr Yi Yan Yang, Group Leader at IBN said, “We have demonstrated the first example of a biodegradable synthetic macromolecule with broad-spectrum antimicrobial activity in mice, unique killing mechanism and no toxicity. Once the polymer finishes its job of killing the bacteria, it will be naturally degraded after three days and will not remain in the body. This antimicrobial agent shows great promise for the treatment and prevention of multidrug-resistant systemic infections.”
“This study illustrates the potential for this new research field we denote as ‘macromolecular therapeutics’ to create entirely new classes of treatments for multiple diseases,” said Dr James Hedrick, Distinguished Research Staff Member, IBM Research – Almaden, San Jose, California. “In 2016, we demonstrated the efficacy of synthetic polymers to combat deadly viral diseases. The current research for treating bacterial infections rounds out our ability to someday treat a spectrum of infectious diseases with a single, new type of mechanism without the onset of resistance.”
To determine whether the bacteria will develop any resistance to the polymer, the team collaborated with Dr Paola Florez de Sessions at A*STAR’s Genome Institute of Singapore and the Cell Engineering group of Dr Simone Bianco at IBM Research – Almaden to perform genomic analysis. They found that the bacteria did not show any resistance development even after multiple treatments with the polymer.
The Latest on: Antimicrobial drug
- Urgent need to find antibiotic alternatives on November 12, 2018 at 5:29 pm
ESR scientist Craig Billington says no new classes of antibiotics have been developed for 30 years, and resistance has arisen to all antimicrobial drugs developed to date. There is international evide... […]
- Antibiotics vital for fighting drug resistant superbugs drastically overused in many countries, WHO report warns on November 12, 2018 at 9:39 am
Key antibiotics which are meant to be used sparingly to ensure they don’t speed up the spread of drug resistant bacterial infections account for more than 50 per cent of prescriptions in some countrie... […]
- Pfizer to help prevent global public health threat of antimicrobial resistance on November 12, 2018 at 5:46 am
Pfizer Pakistan in recognition of World Antibiotic Awareness Week ... risky to perform because of the risk of becoming infected while in hospital by a multi-drug resistant pathogen. SM Wajeeh, country ... […]
- UK pay-for-performance program reduced antibiotic prescribing on November 9, 2018 at 3:15 am
“Antimicrobial resistance is a serious public health problem and a global threat with an estimated 10 million people a year dying of drug-resistant infections by 2050,” Balinskaite and colleagues wrot... […]
- New single-dose antibiotic safe and effective for uncomplicated gonorrhea on November 8, 2018 at 5:17 am
gonorrhoeae necessitate the urgent development of new antimicrobial agents.” The researchers conducted a randomized, open-label phase 2 clinical trial to determine the safety and effectiveness of the ... […]
- Racial/Ethnic Disparities in Antimicrobial Drug Use, United States, 2014–2015 on November 6, 2018 at 9:29 pm
Emerging Infectious Diseases. 2018;24(11):2126-2128. Using a US nationwide survey, we measured disparities in antimicrobial drug acquisition by race/ethnicity for 2014–2015. White persons reported twi... […]
- 4 months after drug approval, Achaogen eyes fire sale on November 5, 2018 at 10:21 am
Antibiotic drug maker Achaogen Inc., which in June won regulatory approval for its first antibiotic drug, said Monday it is exploring "strategic alternatives," including a possible sale or merger, as ... […]
- Is the super antibiotic world badly needs finally here? on November 4, 2018 at 5:19 pm
That is why Japanese pharma company Shionogi’s new antibiotic is making the medical world sit up and take note. The new drug, Cefiderocol, can hoodwink drug resistant pathogens and kill them. […]
- First Databank to Present Poster on Knowledge Management of Drug Information for Antibiotic Stewardship at AMIA Conference on November 2, 2018 at 3:03 am
FDB (First Databank, Inc.), the leading provider of clinical drug knowledge that helps improve medication-related decisions and patient outcomes, today announced that it will present a poster by a tea... […]
- Drug kills antibiotic-resistant bacteria on November 1, 2018 at 9:21 pm
Antibiotic resistance is a major obstacle that modern medicine is currently grappling with. It has created crisis situations around the world, and researchers are trying to find solutions. […]
via Google News and Bing News